Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?
Share this article Share this article EXTON, Pa., Feb. 10, 2021 /PRNewswire/ -- Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla. 1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb's acquisition of Celgene, considering future regulatory conflicts with BMS' pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla. Amgen's purch...
Source: prnewswire.com